Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis

Journal of Neuroscience Research

Volumn 47, Issue 5, 1997, Pages 531-538

  Liu, X ^a   Linnington, C ^b   Webster, H D F ^a,c   Lassmann, S ^b   Yao, D L ^a   Hudson, L D ^a   Wekerle, H ^b   Kreutzberg, G W ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN BASIC PROTEIN; SOMATOMEDIN C;

ADOLESCENT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DRUG EFFECT; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INSULIN-LIKE GROWTH FACTOR I; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 0031044489     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19970301)47:5<531::AID-JNR8>3.0.CO;2-I     Document Type: Article

References (31)

1. Barres BA, Schmid R, Sendnter M, Raff MC (1993): Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118:283-295.
2. Beck KD, Powell-Braxton L, Widmer H-R, Valverde J, Hefti F (1995): Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14:717-730.
3. Ben-Nun A, Wekerle H, Cohen IR (1981): The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11:195-199.
4. Carson MJ, Behringer RR, Brinster RL, McMorris FA (1993): Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10:729-740.
5. Clark R, Strasser J, McCabe S, Robbins K, Jardieu P (1993): Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 92:540-548.
6. Grinspan JB, Stern J, Franceschini B, Yasuda T, Pleasure D (1994): Protein growth factors as potential therapies for central nervous system demyelinative disorders. Ann Neurol 36 (Suppl.):S140-S142.
7. Hsu S-M, Raine L, Fanger H (1981): Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580.
8. Huitinga I, Van Rooijen N, De Groot CJA, Uitdehaag BMJ, Dijkstra CD (1990): Supression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 172:1025-1033.
9. Kojima K, Berger T, Lassmann H, Hinze-Seich D, Zhang Y, Gehrmann J, Reske K, Wekerle H, Linington C (1994): Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100β molecule, a calcium binding protein of astroglia. J Exp Med 180:817-830.
10. Komoly S, Hudson LD, Webster H de F, Bondy CA (1992): Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci U S A 89:1894-1898.
11. Kunz J, Krause D, Gehrmann J, Dermietzel R (1995): Changes in the expression pattern of blood-brain barrier-associated pericytic aminopeptidase N (pAP N) in the course of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 59:41-55.
12. Lannes-Vieira J, Gehrmann J, Kreutzberg GW, Wekerle H (1994): The inflammatory lesion of T cell line transferred experimental autoimmune encephalomyelitis of the Lewis rat: Distinct nature of parenchymal and perivascular infiltrates. Acta Neuropathol (Berl) 87:435-442.
13. Lassmann H, Brunner C, Bradl M, Linington C (1988): Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol (Berl) 75:566-576.
14. Liu X, Yao D-L, Bondy CA, Brenner M, Hudson LD, Zhou J, Webster H de F (1994): Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci 5:418-430.
15. Liu X, Yao D-L, Webster H de F (1995): Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult Scler 1:2-9.
16. Martin R, McFarland HF (1995): Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 32:121-182.
17. Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, Palmiter RD (1988): Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123:2827-2833.
18. McMorris FA, McKinnon RD (1996): Regulation of oligodendrocyte development and CNS myelination by growth factors: Prospects for therapy of demyelinating disease. Brain Pathol 6:313-329.
19. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW (1986): Insulin-like growth factor I/somatomedin C: A potent inducer of oligodendrocyte development. Proc Natl Acad Sci U S A 83:822-826.
20. Mozell RL, McMorris FA (1991): Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res 30:382-390.
21. Racke MK, Sriram S, Carlino J, Cannella B, Raine CS, McFarlin DE (1993): Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 2. J Neuroimmunol 46:175-183.
22. Racke MK, Burnett D, Pak S-H, Albert PS, Cannella B, Raine CS, McFarlin DE, Scott DE (1995): Retinoid treatment of experimental allergic encephalomyelitis: IL-4 production correlates with improved disease course. J Immunol 154:450-458.
23. Selmaj KW, Raine CS (1995): Experimental autoimmune encephalomyelitis: Immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 45 (Suppl. 6):S44-S49.
24. Sommer N, Loschmann P-A, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dichgans J, Martin R (1995): The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1:244-248.
25. Tapson VF, Boni-Schnetzler M, Pilch PF, Center DM, Berman JS (1988): Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest 82:950-957.
26. Vandenbark AA, Hashim G, Offner H (1993): TCR peptide therapy in autoimmune diseases. Intern Rev Immunol 9:251-276.
27. Webster H de F (1997): Growth factors and myelin regeneration in multiple sclerosis. Mult Scler (in press).
28. Xu X, Mardell C, Xian CJ, Zola H, Read LC (1995): Expression of functional insulin-like growth factor-1 receptor on lymphoid cell subsets of rats. Immunology 85:394-399.
29. Yao D-L, West NR, Bondy CA, Brenner M, Hudson LD, Zhou J, Collins GH, Webster H de F (1995a): Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration. J Neurosci Res 40:647-659.
30. Yao D, Liu X, Hudson LD, Webster H de F (1995b): Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 92:6190-6194.
31. Yao D-L, Liu X, Hudson LD, Webster H de F (1996): Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci 58:1301-1306.